Target intelligence / Profile preview

Thoracic sympathetic trunk

Molecular classification
Other (anatomical structure, chain of autonomic ganglia), Not a molecule, not a receptor, not a transporter, not a channel, not an enzyme
01

Overview

The thoracic sympathetic trunk is an anatomical structure consisting of 11–12 sympathetic ganglia running along each side of the thoracic vertebral column. It is continuous with the cervical sympathetic trunk superiorly and the lumbar sympathetic trunk inferiorly. The trunk allows preganglionic sympathetic fibers from the thoracic spinal cord to synapse and distribute broadly to thoracic viscera (including heart, lungs, and esophagus) and contribute to splanchnic nerves that supply abdominal organs. The trunk is involved in mediating autonomic (fight-or-flight) responses, regulating cardiac function, blood pressure, and other visceral activities, but it is not a single targetable molecule or receptor. There is no known drug that specifically "targets" the thoracic sympathetic trunk; its function may be affected by procedures such as surgical sympathectomy, which interrupts autonomic signaling for medical purposes. Damage or intentional disruption can result in clinical syndromes affecting autonomic regulation, such as Horner’s syndrome and complex regional pain syndrome.

Other names
Thoracic sympathetic chainThoracic part of sympathetic trunk
02

Mechanism of action

Not applicable as a drug target; interventions (e.g., block or excision) disrupt sympathetic efferent signaling to organs

03

Biological functions

Autonomic regulation of heart rate, blood pressure, sweat gland secretion, pupil diameter, and other visceral processesCoordination of fight-or-flight responses
04

Disease associations

Can be involved in complex regional pain syndromeDamage can contribute to Horner’s syndromeTargeted in certain surgeries for pain or excessive sweating, but not a molecular therapeutic target
05

Safety considerations

Damage risks include hypotension, bradycardia, loss of sweating, autonomic dysreflexia, and Horner’s syndrome
06

Interacting drugs

None (drugs do not bind or target the trunk itself; interventions are generally surgical, such as sympathectomy, rather than pharmacological)
07

Biomarkers

None (no molecular biomarker for “thoracic sympathetic trunk” function or integrity)

Beyond the preview

Go deeper on Thoracic sympathetic trunk.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thoracic sympathetic trunk.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call